NGM Biopharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NGM Biopharmaceuticals, Inc.
NGM said a Merck-partnered C3 inhibiting antibody has failed a Phase II study in geographic atrophy, after the biotech’s wholly owned NASH candidate missed in a Phase IIb study in 2021.
Emerging Company Profile: Harvesting blood and tissue samples from patients treated with PD-1 immunotherapy, OncoResponse is developing antibodies it believes can transform cold solid tumors into hot.
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
NGM will not proceed with a Phase III study in F2/F3 NASH following failure to show fibrosis benefit in Phase IIb. Analysts say this setback could portend disappointing readouts for other NASH players.
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.